Trial Profile
Phase II clinical study of chidamide monotherapy in the treatment of relapsed or refractory extranodal nasal type NK/T cell lymphoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2018
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- 03 Apr 2018 New trial record